Connection

Gregory Grabowski to Humans

This is a "connection" page, showing publications Gregory Grabowski has written about Humans.
Connection Strength

0.557
  1. More Than One-third of Orthopaedic Applicants Are in the Top 10%: The Standardized Letter of Recommendation and Evaluation of Orthopaedic Resident Applicants. Clin Orthop Relat Res. 2021 08 01; 479(8):1703-1708.
    View in: PubMed
    Score: 0.029
  2. Classification in Brief: Subaxial Cervical Spine Injury Classification and Severity Score System. Clin Orthop Relat Res. 2020 10; 478(10):2390-2398.
    View in: PubMed
    Score: 0.028
  3. Epidural Abscess Caused by Gas-Producing Clostridium Septicum: A Case Report. JBJS Case Connect. 2019 Dec; 9(4):e0282.
    View in: PubMed
    Score: 0.026
  4. Trends in the Treatment of Single and Multilevel Cervical Stenosis: A Review of the American Board of Orthopaedic Surgery Database. J Bone Joint Surg Am. 2017 Sep 20; 99(18):e99.
    View in: PubMed
    Score: 0.022
  5. HIV in Orthopaedic Surgery. J Am Acad Orthop Surg. 2017 Aug; 25(8):569-576.
    View in: PubMed
    Score: 0.022
  6. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017 03 02; 543(7643):108-112.
    View in: PubMed
    Score: 0.021
  7. Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology. PLoS One. 2015; 10(3):e0118771.
    View in: PubMed
    Score: 0.019
  8. The LIMP-2/SCARB2 binding motif on acid ?-glucosidase: basic and applied implications for Gaucher disease and associated neurodegenerative diseases. J Biol Chem. 2014 Oct 24; 289(43):30063-74.
    View in: PubMed
    Score: 0.018
  9. CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings. Mol Genet Metab. 2015 Feb; 114(2):233-241.
    View in: PubMed
    Score: 0.018
  10. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum Mol Genet. 2014 Aug 01; 23(15):3943-57.
    View in: PubMed
    Score: 0.017
  11. Orthopaedic fellowship selection criteria: a survey of fellowship directors. J Bone Joint Surg Am. 2013 Oct 16; 95(20):e154.
    View in: PubMed
    Score: 0.017
  12. Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model. Mol Genet Metab. 2014 Feb; 111(2):163-71.
    View in: PubMed
    Score: 0.017
  13. Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease. PLoS One. 2013; 8(3):e57560.
    View in: PubMed
    Score: 0.016
  14. Tissue-specific effects of saposin A and saposin B on glycosphingolipid degradation in mutant mice. Hum Mol Genet. 2013 Jun 15; 22(12):2435-50.
    View in: PubMed
    Score: 0.016
  15. Bone graft and bone graft substitutes in spine surgery: current concepts and controversies. J Am Acad Orthop Surg. 2013 Jan; 21(1):51-60.
    View in: PubMed
    Score: 0.016
  16. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program. 2012; 2012:13-8.
    View in: PubMed
    Score: 0.015
  17. Ex vivo and in vivo effects of isofagomine on acid ?-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem. 2012 Feb 03; 287(6):4275-87.
    View in: PubMed
    Score: 0.015
  18. Esophageal and vertebral artery injuries during complex cervical spine surgery--avoidance and management. Orthop Clin North Am. 2012 Jan; 43(1):63-74, viii.
    View in: PubMed
    Score: 0.015
  19. Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease. Autophagy. 2010 Jul; 6(5):648-9.
    View in: PubMed
    Score: 0.014
  20. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One. 2010 May 20; 5(5):e10750.
    View in: PubMed
    Score: 0.013
  21. Multi-system disorders of glycosphingolipid and ganglioside metabolism. J Lipid Res. 2010 Jul; 51(7):1643-75.
    View in: PubMed
    Score: 0.013
  22. Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse. Hum Mol Genet. 2010 Feb 15; 19(4):634-47.
    View in: PubMed
    Score: 0.013
  23. Gaucher disease: resetting the clinical and scientific agenda. Am J Hematol. 2009 Apr; 84(4):205-7.
    View in: PubMed
    Score: 0.012
  24. Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse model. J Lipid Res. 2006 Oct; 47(10):2161-70.
    View in: PubMed
    Score: 0.010
  25. Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradation. J Biol Chem. 2003 Aug 22; 278(34):31918-23.
    View in: PubMed
    Score: 0.008
  26. Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol Dis. 2003 Jan-Feb; 30(1):90-6.
    View in: PubMed
    Score: 0.008
  27. Ex vivo localization of the mouse saposin C activation region for acid beta-glucosidase. Mol Genet Metab. 2002 Jul; 76(3):189-200.
    View in: PubMed
    Score: 0.008
  28. Resident Wellness During the COVID-19 Pandemic: A Nationwide Survey of Orthopaedic Residents. J Am Acad Orthop Surg. 2021 May 15; 29(10):407-413.
    View in: PubMed
    Score: 0.007
  29. Keloid and Hypertrophic Scar Formation, Prevention, and Management: Standard Review of Abnormal Scarring in Orthopaedic Surgery. J Am Acad Orthop Surg. 2020 May 15; 28(10):e408-e414.
    View in: PubMed
    Score: 0.007
  30. Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. Mol Genet Metab. 2020 07; 130(3):164-169.
    View in: PubMed
    Score: 0.007
  31. Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease. EBioMedicine. 2020 May; 55:102735.
    View in: PubMed
    Score: 0.007
  32. An unexpected player in Gaucher disease: The multiple roles of complement in disease development. Semin Immunol. 2018 06; 37:30-42.
    View in: PubMed
    Score: 0.006
  33. A Prospective Multicenter Evaluation of the Value of the On-Call Orthopedic Resident. J Grad Med Educ. 2018 Feb; 10(1):91-94.
    View in: PubMed
    Score: 0.006
  34. Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease. EBioMedicine. 2018 Feb; 28:251-260.
    View in: PubMed
    Score: 0.006
  35. Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice. Hum Mol Genet. 2016 12 01; 25(23):5126-5141.
    View in: PubMed
    Score: 0.005
  36. Association Between Progranulin and Gaucher Disease. EBioMedicine. 2016 Sep; 11:127-137.
    View in: PubMed
    Score: 0.005
  37. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease. Mol Ther. 2016 06; 24(6):1019-1029.
    View in: PubMed
    Score: 0.005
  38. Activation of p38 Mitogen-Activated Protein Kinase in Gaucher's Disease. PLoS One. 2015; 10(8):e0136633.
    View in: PubMed
    Score: 0.005
  39. An in vivo model of human small intestine using pluripotent stem cells. Nat Med. 2014 Nov; 20(11):1310-4.
    View in: PubMed
    Score: 0.005
  40. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E435-44.
    View in: PubMed
    Score: 0.004
  41. Endogenous ?-glucocerebrosidase activity in Abca12?/?epidermis elevates ceramide levels after topical lipid application but does not restore barrier function. J Lipid Res. 2014 Mar; 55(3):493-503.
    View in: PubMed
    Score: 0.004
  42. Venous thrombosis in athletes. J Am Acad Orthop Surg. 2013 Feb; 21(2):108-17.
    View in: PubMed
    Score: 0.004
  43. Saposins utilize two strategies for lipid transfer and CD1 antigen presentation. Proc Natl Acad Sci U S A. 2012 Mar 20; 109(12):4357-64.
    View in: PubMed
    Score: 0.004
  44. Gaucher disease glucocerebrosidase and a-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011 Jul 08; 146(1):37-52.
    View in: PubMed
    Score: 0.004
  45. Acid ?-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter a-synuclein processing. Ann Neurol. 2011 Jun; 69(6):940-53.
    View in: PubMed
    Score: 0.004
  46. The role of UDP-Glc:glycoprotein glucosyltransferase 1 in the maturation of an obligate substrate prosaposin. J Cell Biol. 2010 May 31; 189(5):829-41.
    View in: PubMed
    Score: 0.003
  47. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood. 2009 Oct 08; 114(15):3181-90.
    View in: PubMed
    Score: 0.003
  48. Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid. J Biol Chem. 2009 May 08; 284(19):12979-88.
    View in: PubMed
    Score: 0.003
  49. Involvement of acid beta-glucosidase 1 in the salvage pathway of ceramide formation. J Biol Chem. 2009 May 08; 284(19):12972-8.
    View in: PubMed
    Score: 0.003
  50. Saposin C: neuronal effect and CNS delivery by liposomes. Ann N Y Acad Sci. 2005 Aug; 1053:237-46.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.